Hypertrophic cardiomyopathy: The need for randomized trials

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting over one million people in Europe.
• It is a leading cause of sudden cardiac death in young individuals.
• Current treatments are empirical, lacking strong clinical evidence for efficacy.

Purpose of the Study:

• To address the unmet need for effective treatments in HCM.
• To explore novel pharmacological strategies targeting the molecular and cellular basis of HCM.
• To pave the way for adequately designed clinical trials to improve patient outcomes.

Main Methods:

• Review of existing pharmacological studies in HCM patients.
• Analysis of emerging evidence on drugs targeting sarcomere protein mutations and pathophysiological abnormalities.
• Identification of critical issues requiring systematic investigation in HCM.

Main Results:

• Limited pharmacological research exists for HCM, with small, non-randomized studies.
• No specific drug has demonstrated a significant impact on HCM outcomes.
• Growing evidence suggests drugs can counteract HCM's molecular and cellular effects.

Conclusions:

• HCM remains an orphan disease with inadequate treatment options.
• Further research and well-designed clinical trials are crucial.
• Targeting molecular pathways offers potential to alter the disease course and improve patient quality of life.